US · SNY
Sanofi
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Paris 75008
- Website
- sanofi.com
Price · as of 2025-12-31
$46.08
Market cap 117.52B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $53.40 | +15.89% |
| Intrinsic Value(DCF) | $156.67 | +240% |
| Graham-Dodd Method(GD) | $20.00 | -56.6% |
| Graham Formula(GF) | $49.80 | +8.07% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $22.02 | $43.60 | $2.42 | $11.20 | $27.50 |
| 2012 | $29.96 | $44.55 | $1.72 | $0.00 | $23.00 |
| 2013 | $32.58 | $40.58 | $3.12 | $0.00 | $0.00 |
| 2014 | $30.61 | $45.70 | $3.58 | $0.00 | $20.00 |
| 2015 | $27.86 | $45.84 | $6.03 | $0.00 | $32.10 |
| 2016 | $30.75 | $47.25 | $5.22 | $0.00 | $16.60 |
| 2017 | $29.21 | $52.35 | $3.90 | $2.00 | $48.30 |
| 2018 | $32.60 | $43.78 | $3.64 | $0.00 | $13.30 |
| 2019 | $38.34 | $46.32 | $2.37 | $0.00 | $17.10 |
| 2020 | $39.41 | $66.84 | $17.32 | $9.90 | $43.40 |
| 2021 | $43.20 | $58.49 | $7.44 | $0.00 | $37.00 |
| 2022 | $41.86 | $63.08 | $10.86 | $2.00 | $45.30 |
| 2023 | $44.32 | $55.70 | $2.06 | $0.00 | $26.80 |
| 2024 | $56.74 | $54.72 | $0.71 | $0.00 | $37.10 |
| 2025 | $47.66 | $45.59 | $3.60 | $20.00 | $49.80 |
AI valuation
Our deep-learning model estimates Sanofi's (SNY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $53.40
- Current price
- $46.08
- AI upside
- +15.89%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$156.67
+240% upside
Graham-Dodd
$20.00
-56.6% upside
Graham Formula
$49.80
+8.07% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNY | Sanofi | $46.08 | 117.52B | -1% | +240% | -57% | +8% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| BMY | Bristol-Myers Squibb Comp… | $62.37 | 127.01B | +7% | -50% | — | -56% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| CVS | CVS Health Corporation | $79.90 | 101.65B | -34% | -49% | — | -73% | 58.52 | 1.38 | 0.26 | 18.90 | — | -2.89 | 13.77% | 2.58% | 0.44% | 2.35% | 5.50% | 0.69% | 1.24 | 3.33 | 0.84 | 0.57 | 8.63 | -6202.00% | 785.00% | 2341.00% | 7.55% | 0.12 | 5.11% | 3.28% | 192.10% | 3.28% | 17.95 | 23.88 | 0.46 | 2.27 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| HCA | HCA Healthcare, Inc. | $529.70 | 118.45B | -26% | -56% | -86% | -18% | 18.12 | -20.40 | 1.63 | 11.03 | 62.49 | -7.53 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 2900.00% | 708.00% | 3641.00% | 6.26% | 0.77 | 18.35% | 0.55% | 10.00% | 8.74% | 14.38 | 22.37 | 2.28 | 2.87 |
| MDT | Medtronic plc | $97.66 | 125.38B | — | -51% | — | -81% | 41.30 | 2.92 | 4.98 | 22.00 | — | -18.12 | 65.19% | 14.89% | 11.97% | — | — | — | 0.51 | 4.85 | 2.65 | 1.91 | 3.03 | — | — | — | 3.26% | 0.73 | — | 2.08% | 86.00% | 2.52% | 36.91 | 33.88 | 5.50 | 3.26 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| VRTX | Vertex Pharmaceuticals In… | $496.83 | 126.19B | -25% | -45% | -71% | -46% | 31.44 | 6.66 | 10.29 | 24.47 | — | 7.25 | 85.03% | 39.43% | 32.74% | 22.54% | 28.97% | 16.24% | 0.21 | 357.95 | 2.90 | 2.24 | -0.24 | -83654.00% | 957.00% | -50413.00% | 2.57% | 0.94 | 22.83% | 0.00% | 0.00% | 1.62% | 25.53 | 38.06 | 10.07 | 12.10 |
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
- CEO
- Olivier Charmeil
- Employees
- 82.88K
- Beta
- 0.37
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($156.67 ÷ $46.08) − 1 = +240% (DCF, example).